JP2016520515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520515A5 JP2016520515A5 JP2016501157A JP2016501157A JP2016520515A5 JP 2016520515 A5 JP2016520515 A5 JP 2016520515A5 JP 2016501157 A JP2016501157 A JP 2016501157A JP 2016501157 A JP2016501157 A JP 2016501157A JP 2016520515 A5 JP2016520515 A5 JP 2016520515A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- lower alkyl
- heterocycle
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789867P | 2013-03-15 | 2013-03-15 | |
| US61/789,867 | 2013-03-15 | ||
| PCT/US2014/023135 WO2014150395A1 (en) | 2013-03-15 | 2014-03-11 | Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520515A JP2016520515A (ja) | 2016-07-14 |
| JP2016520515A5 true JP2016520515A5 (enExample) | 2017-04-13 |
Family
ID=51580758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501157A Pending JP2016520515A (ja) | 2013-03-15 | 2014-03-11 | 抗ｐｃｓｋ９化合物および心血管疾患の治療および／または予防のための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10131637B2 (enExample) |
| EP (1) | EP2968318A4 (enExample) |
| JP (1) | JP2016520515A (enExample) |
| CN (1) | CN105473141A (enExample) |
| AU (1) | AU2014237198A1 (enExample) |
| BR (1) | BR112015023193A2 (enExample) |
| CA (1) | CA2904662A1 (enExample) |
| WO (1) | WO2014150395A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014028585B1 (pt) | 2012-05-17 | 2020-12-22 | Genentech , Inc | processo para fabricação de aminoácidos, e seus intermediários |
| EP2850200A1 (en) | 2012-05-17 | 2015-03-25 | Genentech, Inc. | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof |
| LT2858989T (lt) | 2012-05-17 | 2020-08-10 | Genentech, Inc. | Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai |
| ES2588878T3 (es) | 2012-05-17 | 2016-11-07 | Array Biopharma, Inc. | Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada |
| ES2582557T3 (es) | 2012-05-17 | 2016-09-13 | Array Biopharma, Inc. | Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina |
| EP3337788A4 (en) | 2015-08-21 | 2019-03-27 | Portola Pharmaceuticals, Inc. | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE |
| HK1260897A1 (zh) | 2015-08-21 | 2019-12-27 | Portola Pharmaceuticals, Inc. | 使用四氢异喹啉小分子来结合并调节pcsk9的蛋白活性的组合物和方法 |
| WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
| CN105214087B (zh) | 2015-10-29 | 2017-12-26 | 陈敏 | Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用 |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| AU2017281332A1 (en) | 2016-06-24 | 2018-12-20 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| TW201823222A (zh) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | 化合物、醫藥組成物及其用途 |
| EP3609882B1 (en) | 2017-03-17 | 2022-07-13 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of pcsk9 |
| EP3746124A4 (en) * | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| EP3826623A4 (en) | 2018-06-25 | 2022-03-23 | Duke University | COMPOSITIONS AND METHODS FOR TREATING CANCER CHARACTERIZED BY PCSK9 EXPRESSION |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| WO2020110008A1 (en) * | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3969620B1 (en) | 2019-05-17 | 2025-06-25 | Regeneron Pharmaceuticals, Inc. | Genome-based methods for reducing cardiovascular risk |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017313A (en) | 1974-09-30 | 1977-04-12 | E. I. Du Pont De Nemours And Company | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process |
| DE3021590A1 (de) | 1980-06-09 | 1981-12-17 | Hoechst Ag, 6000 Frankfurt | 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen |
| WO2000071511A2 (en) * | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| US20050288340A1 (en) | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| JP2009533419A (ja) | 2006-04-11 | 2009-09-17 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルホンアミド化合物 |
| AR066042A1 (es) * | 2007-04-13 | 2009-07-22 | Novartis Ag | Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9) |
| US20090275053A1 (en) | 2008-04-30 | 2009-11-05 | Board Of Regents, The University Of Texas System | Cell-based pcsk9 screening assay |
| US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
| US20110009628A1 (en) * | 2009-07-08 | 2011-01-13 | Haiyan Liu | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same |
| EP2483266B1 (en) | 2009-10-01 | 2015-02-25 | Cadila Healthcare Limited | Compounds for the treatment of dyslipidemia and related diseases |
| WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| WO2013177536A2 (en) * | 2012-05-25 | 2013-11-28 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| AR092924A1 (es) * | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
-
2014
- 2014-03-11 EP EP14768980.6A patent/EP2968318A4/en not_active Withdrawn
- 2014-03-11 BR BR112015023193A patent/BR112015023193A2/pt active Search and Examination
- 2014-03-11 JP JP2016501157A patent/JP2016520515A/ja active Pending
- 2014-03-11 AU AU2014237198A patent/AU2014237198A1/en not_active Abandoned
- 2014-03-11 US US14/767,126 patent/US10131637B2/en active Active
- 2014-03-11 CN CN201480016207.6A patent/CN105473141A/zh active Pending
- 2014-03-11 CA CA2904662A patent/CA2904662A1/en not_active Abandoned
- 2014-03-11 WO PCT/US2014/023135 patent/WO2014150395A1/en not_active Ceased
-
2017
- 2017-12-01 US US15/829,028 patent/US20180079730A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6577570B2 (ja) | インフルエンザウイルス感染に使用するためのインドール類 | |
| US7872037B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| Suzuki et al. | Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors | |
| KR101472248B1 (ko) | 뒤시엔느 근이영양증의 치료 | |
| US8461177B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JOP20210017A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| Pan et al. | 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors | |
| US8148428B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
| ME02696B (me) | MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI | |
| AU2010253820A1 (en) | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation | |
| JP2015517976A (ja) | アレナウイルス感染症の治療のための抗ウイルス薬 | |
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| RU2008136859A (ru) | НИЗКОМОЛЕКУЛЯРНЫЕ МОДУЛЯТОРЫ АКТИВНОСТИ Trp-p8 | |
| CN101537001A (zh) | 作为jak-stat3信号通路抑制剂的化合物的应用 | |
| RU2017112299A (ru) | Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения | |
| Watterson et al. | Acridone-Based Inhibitors of Inosine 5 ‘-Monophosphate Dehydrogenase: Discovery and SAR Leading to the Identification of N-(2-(6-(4-Ethylpiperazin-1-yl) pyridin-3-yl) propan-2-yl)-2-fluoro-9-oxo-9, 10-dihydroacridine-3-carboxamide (BMS-566419) | |
| JP2014521705A5 (enExample) | ||
| CN103497179A (zh) | 含苯并咪唑结构单元的嘧啶衍生物及其制备方法和用途 | |
| Çıkla et al. | Synthesis and evaluation of antiviral, antitubercular and anticancer activities of some novel thioureas derived from 4-aminobenzohydrazide hydrazones | |
| Bischoff et al. | Novel pharmacological modulators of autophagy and therapeutic prospects | |
| TWI454445B (zh) | 聯苯醯胺衍生小分子之製備與醫藥用途 | |
| Lang et al. | Discovery of C-5 pyrazole-substituted pyrrolopyridine derivatives as potent and selective inhibitors for janus kinase 1 | |
| US10975059B2 (en) | Small molecule BRD4 modulators for HIV epigenetic regulation | |
| Yao et al. | Design, synthesis and cytotoxic evaluation of novel imatinib amide derivatives that target Abl kinase | |
| WO2026006142A1 (en) | Azole compounds useful as inhibitors of voltage-dependent anion channel oligomerization |